Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 162.54%.

  • InMed Pharmaceuticals' EBITDA Margin fell 264300.0% to 162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 166.64%, marking a year-over-year decrease of 212700.0%. This contributed to the annual value of 159.76% for FY2025, which is 174700.0% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' EBITDA Margin is 162.54%, which was down 264300.0% from 138.56% recorded in Q2 2025.
  • InMed Pharmaceuticals' EBITDA Margin's 5-year high stood at 20.43% during Q2 2023, with a 5-year trough of 1615.6% in Q4 2021.
  • Its 5-year average for EBITDA Margin is 473.14%, with a median of 180.85% in 2023.
  • Per our database at Business Quant, InMed Pharmaceuticals' EBITDA Margin skyrocketed by 15084400bps in 2023 and then plummeted by -1376900bps in 2024.
  • InMed Pharmaceuticals' EBITDA Margin (Quarter) stood at 1615.6% in 2021, then soared by 72bps to 447.25% in 2022, then surged by 71bps to 131.49% in 2023, then tumbled by -53bps to 201.65% in 2024, then rose by 19bps to 162.54% in 2025.
  • Its EBITDA Margin was 162.54% in Q3 2025, compared to 138.56% in Q2 2025 and 168.46% in Q1 2025.